No registrations found.
ID
Source
Brief title
Health condition
Muscle function
Sponsors and support
Intervention
Outcome measures
Primary outcome
isokinetic MVC defined as peak force at an angular velocity of 180°/s, as determined by dynamometry of the upper leg, before and immediately after, 3h after, and 1, 2 and 3 days after eccentric exercise
Secondary outcome
Isokinetic MVC defined as peak force at an angular velocity of 90°/s, determined by dynamometry of the upper leg, before and immediately after, 3h after, and 1, 2 and 3 days after eccentric exercise
Isometric MVC defined as peak force at a knee angle of 60° determined by dynamometry of the upper leg, before and immediately after, 3h after, and 1, 2 and 3 days after eccentric exercise
Jump height assessed by vertical countermovement jump before and immediately after, 3h after, and 1, 2 and 3 days after eccentric exercise.
Thigh circumference according to ISAK standards.
Delayed onset muscle soreness (DOMS) assessed by VAS (100 mm) at baseline, immediately after and at 3, 24, 48, 72 and 96h post exercise.
Change in biomarkers of inflammation and immune function
Background summary
Delayed onset muscle soreness (DOMS) develops 24-48 hours after strenuous exercise biased toward eccentric (muscle lengthening) muscle actions and is a symptom of exercise-induced muscle damage. Soreness is accompanied by a prolonged strength loss, a reduced range of motion, and elevated levels of muscle damage markers in the blood. Reported study results are not consistent with respect to the acute benefits of protein supplementation on reductions in muscle damage and enhanced recovery of muscle function. We hypothesize that supplementation with whey protein is efficacious in improving recovery following eccentric exercise when given in the days before and after the exercise.
Study objective
Whey protein supplementation during the days before and after muscle-damaging eccentric exercise improves recovery of muscle strength, compared to placebo
Study design
Before and immediately after, 3h after, and 1, 2 and 3 days after eccentric exercise
Intervention
A whey protein supplement and an isocaloric placebo supplement, starting 4 days before muscle damaging exercise
Inclusion criteria
Substantial
Male
Age ≥18 and ≤35 years.
BMI ≥18.5 and ≤27.5 kg/m2
Healthy as assessed by the NIZO lifestyle and health questionnaire.
Recreationally active, defined as performing physical activities on a recreational basis for a maximal duration of 5 hours per week.
Veins suitable for cannulation (blood sampling)
Procedural
Having given written informed consent.
Willing to comply with study procedures.
Ability to follow Dutch verbal and written instructions.
Availability of internet connection.
Accept use of all encoded data, including publication, and the confidential use and storage of all data for 15 years.
Accept disclosure of the financial benefit of participation in the study to the authorities concerned.
Exclusion criteria
Substantial
Having a history of medical or surgical events that may significantly affect the study outcome, to be decided by the principal investigator.
Participating in resistance exercise or exercise with a major eccentric component (e.g. (trail) running, football, volleyball, basketball, track and field) in the last 6 months.
Regular use of the following medication: corticosteroids, antihistamines, NSAID.
Smoking.
Regular use of protein supplements.
Mental status that is incompatible with the proper conduct of the study
A self-reported reported lactose intolerance, allergy or sensitivity to dairy ingredients
Evidence of current excessive alcohol consumption (>21 units/week) or drug (ab)use, and not willing/able to stop this during the study.
Reported slimming or medically prescribed diet
Procedural
Participation in any clinical trial including blood sampling and/or administration of substances up to 30 days before Day 01 of this study
Recent blood donation (<1 month prior to Day 01 of the study)
Personnel of HAN, NIZO and FC, their partner and their first and second degree relatives
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL7550 |
| CCMO | NL68027.072.18 |
| OMON | NL-OMON45952 |